ClinicalTrials.gg
RecruitingNCT07729683Ckd-WEEDUpdated Jul 27, 2026

Evaluation of the Effect of a Daily Dose of Wakame Seaweed on Reducing Circulating Concentrations of Advanced Glycation End Products in Patients With Stage III Chronic Kidney Disease

An interventional study of Consumption of wakame in Chronic Kidney Disease, sponsored by Groupe Hospitalier de la Rochelle Ré Aunis. Recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Groupe Hospitalier de la Rochelle Ré Aunis · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Persistent glomerular hyperfiltration is a characteristic feature of the early stages of kidney disease and represents a factor in the progression of chronic kidney disease (CKD). In this context, the benefit of low-protein diets (less than 0.8g/kg/day) has been demonstrated in slowing the progression of CKD, although the underlying pathophysiological mechanisms remain unclear.

Some studies suggest that the effects of protein on renal hemodynamics are primarily linked to the quality of the protein, particularly the amount of AGEs (Advanced Glycation End Products) consumed.

Recently, edible seaweeds have gained popularity in Western countries due to their anti-inflammatory, anti-diabetic, and antihypertensive properties. These seaweeds are also associated with the above-average longevity of certain Asian populations who consume them daily. Wakame seaweed (Undaria pinnatifida), which is locally harvested along the French Atlantic coast, has shown promising biological properties, notably antihypertensive and anti-diabetic effects. It has also been recently demonstrated that fucoxanthin, a compound found in high concentrations in wakame, possesses strong anti-AGE activity.

Dietary modifications are essential for nephroprotection, but they are often difficult to implement. This highlights the need to develop approaches that are both acceptable on a daily basis and sustainable in the long term for patients.

A Michelin-starred chef, known for regularly incorporating seaweed into his cuisine, is a sponsor of the project and has validated a set of adapted recipes that will be offered to participants to accompany the daily wakame supplementation.

The investigator's hypothesis is that a daily dose (5 grams of French wakame, dehydrated at low temperature and in flake form), equivalent to the average daily intake in Japan, could reduce circulating AGE levels in patients with stage III CKD. This would provide an additional protective effect when combined with the standard low-protein diet, helping to slow the progression of CKD over the long term.

Read the detailed description

Persistent glomerular hyperfiltration is a characteristic feature of the early stages of chronic kidney disease (CKD), particularly observed in the initial phases of diabetic nephropathy, and constitutes a major factor in the progression of kidney failure. In this context, the benefit of low-protein diets (less than 0.8g/kg/day) in slowing CKD progression has been demonstrated, though the underlying pathophysiological explanation remains unclear.

Among the proposed mechanisms, a study demonstrated that an oral protein load (cooked red meat) led to a significant 26% increase in glomerular filtration rate, measured by inulin clearance, in healthy subjects 90 minutes after ingestion. This protein-induced glomerular hyperfiltration is used to assess renal functional reserve, defined as the kidney's ability to increase renal blood flow and GFR after a protein load, via modulation of intrarenal hemodynamics.

The precise mechanisms underlying these hemodynamic and functional changes remain controversial. A study suggested that the renal hemodynamic effects of a protein load are primarily related to the amount of Advanced Glycation End Products (AGEs) ingested. Indeed, the experimental models used to study renal functional reserve (e.g., amino acid perfusions, red meat meals) also involved significant AGE exposure.

AGEs are formed through non-enzymatic glycation reactions, where sugars bind to peptides or nucleic acids, leading to cellular aging via increased ROS (Reactive Oxygen Species) production and activation of inflammatory pathways. Methylglyoxal (MG) and Carboxymethyl-lysine (CML), two major circulating and tissue AGEs, are predominantly cleared by the kidneys and accumulate with age.

While it was previously thought that AGEs were primarily endogenously produced, it is now well established that dietary intake is a significant source, especially via harmful cooking methods (high-temperature cooking with oil and little water), both in healthy individuals and those with CKD. An oral AGE load has been shown to significantly increase circulating CML levels within 90 minutes.

In a pilot human study, it has been demonstrated that an oral protein load rich in AGEs led to greater mobilization of renal functional reserve (increased renal blood flow and renal oxidative metabolism) compared to an iso-protein, low-AGE load. This finding supports a key role for AGE content and protein quality, beyond quantity alone, in the nephroprotective effects of low-protein diets.

In animal models, aged mice fed an AGE-rich diet developed chronic kidney disease with glomerular and tubular damage. In humans, dietary AGE intake contributes to inter-individual variation in CKD progression. Reducing dietary AGE intake has been shown to decrease plasma and peritoneal dialysis AGE levels in non-diabetic dialysis patients. Additionally, two months of treatment with sevelamer, a phosphate binder, in patients with diabetic nephropathy (stages II to IV) led to a significant reduction in MG and CML, HbA1c, and markers of inflammation and oxidative stress, while increasing levels of the AGE receptor AGER1. However, this approach involves adding another medication to patients already under high therapeutic pressure, with associated risks of poor adherence.

Seaweed consumption is an ancestral practice in Asia, where life expectancy is generally higher than in Western countries. Regular seaweed consumption may partly explain this longevity. Brown seaweeds are exceptionally rich in fiber, phlorotannins, carotenoids, trace elements (copper, chromium, zinc, selenium, manganese, iron), and vitamins (C, B1, B2, B6, B12). Recent studies have shown that the seaweed Ishige okamurae, native to Okinawa, exhibits anti-AGE properties. The phlorotannin diphlorethohydroxycarmalol (DPHC) from Ishige okamurae has been shown to prevent diabetic nephropathy in mouse mesangial cells by inhibiting AGE-RAGE interactions.

The seaweed Undaria pinnatifida (Up), commonly known as wakame in Japan, has been present along the French Atlantic coast since the 1970s, having been introduced from Asia. Low-temperature dehydration (40°C), in line with traditional Asian methods, helps preserve its biological properties.

Wakame has demonstrated various biological activities, including ACE (angiotensin-converting enzyme) inhibition. A daily intake of 5g over 8 weeks resulted in a 10 mmHg reduction in blood pressure in both Japanese and non-Japanese hypertensive individuals. Wakame also improves postprandial glycemic control in both humans and rats via PPAR activation and improved GLUT4 membrane translocation in myocytes. Fucoxanthin, found in high concentrations in wakame, has recently been shown to possess potent anti-AGE activity.

Wakame also has a pleasant umami and iodine-rich taste with a texture appreciated by chefs, making it a more appealing option for daily use among patients already facing heavy therapeutic burdens.

Dietary changes are essential in nephroprotection, but they are difficult to implement, underlining the importance of developing strategies that are practical, acceptable, and sustainable for patients.

A Michelin-starred chef, known for his regular use of seaweed in cuisine, is the project sponsor and has validated a set of tailored recipes that will be provided to participants to accompany daily wakame supplementation. Some of these recipes are presented in the appendix of the protocol.

To investigator's knowledge, no study has yet evaluated the impact of daily wakame intake on the reduction of circulating AGE concentrations or on nephroprotection.

Thje investigator's hypothesis is that a daily dose of 5g of wakame (equivalent to the average daily intake in Japan) could reduce circulating AGE concentrations (specifically methylglyoxal). Lowering AGE levels beyond that achieved by protein restriction alone could offer additional protection against CKD progression.

02

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Advanced Glycation End Products
  • AGEs
  • Chronic kidney disease (CKD)
  • Wakame seaweed
03

In context

Renal Insufficiency, Chronic

3,090 studies on the registry are indexed under Renal Insufficiency, Chronic; 698 are open to participants now.

This study's planned enrollment of 30 is below the median of 73 across 2,157 interventional studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

Groupe Hospitalier de la Rochelle Ré Aunis is the lead sponsor of 22 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients not under legal protection
  • Patients aged ≥ 18 and \< 90 years
  • Patients with stage IIIA-B chronic kidney disease (CKD) (estimated by CKD-EPI ≥ 30 mL/min and \< 60 mL/min)
  • Patients receiving optimized nephroprotective treatment (ACE inhibitors, SGLT2 inhibitors)
  • Patients who have signed the form
  • Patients not participating in another clinical study
  • Patients affiliated with or benefiting from a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Adult patients under legal protection
  • Patients under 18 years old or over 90 years old
  • Patients with uncontrolled thyroid disorders
  • Patients with decompensated heart failure
  • Patients consuming other dietary supplements containing seaweed or iodine (e.g., multivitamins)
  • Pregnant or breastfeeding women
  • Patients with acute kidney injury
  • Patients who decline to participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Consumption of 5g/day of wakame (Undoria pinnatifida) during one of the three meals of the day for a period of three months.

    Dietary Supplement: Consumption of wakame

Interventions

  • Dietary supplementConsumption of wakame

    Consumption of 5g/day of wakame during one of the three meals of the day during three months.

06

What researchers measure

Primary outcomes

  1. Circulating AGE

    Circulating AGE measurement by plasma methylglyoxal (MG) measurement at M3

    Time frame: From enrollment to the end of 3 months follow-up

Secondary outcomes

  1. Proteinuria

    Proteinuria measurement (in g/g creatinine in urine) at M3

    Time frame: From enrollment to the end of 3 months follow-up

  2. Ambulatory blood pressure

    Ambulatory blood pressure (systolic and diastolic blood pressure) monitoring (ABPM) over 24 hours at M3

    Time frame: From enrollment to the end of 3 months follow-up

  3. Plasma creatinine clearance

    Calculation of estimated plasma creatinine clearance (CKD-epi) at M3

    Time frame: From enrollment to the end of 3 months follow-up

  4. HbA1c

    HbA1c measurement at M3

    Time frame: From enrollment to the end of 3 months follow-up

  5. Lipid profile

    Lipid profile (TG, LDLc, and HDLc) measurement at M3

    Time frame: From enrollment to the end of 3 months follow-up

  6. TSH

    TSH measurement at M3

    Time frame: From enrollment to the end of 3 months follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be made available with publication. A Digital Object Identifier will be used and Data will be available at www.recherche.data.gouv.fr

Supporting information: Study protocol

Time frame: Data will be available immediately following publication

Access criteria: Researchers who provide a methodologically sound proposal will have access to the data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 21 months after the start.

Of 576 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 21 months is close to that.

Counting every sponsor, half of 616 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Jul 27, 2026
StartActual
Jan 27, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07729683
Lead sponsor
Groupe Hospitalier de la Rochelle Ré Aunis
Collaborators
Clinisciences
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Jan 27, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Cécile Duchiron
Contact
cecile.duchiron@ght-atlantique17.fr
+335 46 68 45 67
Gabrielle Laetitia Normand
study director · Groupe Hospitalier de la Rochelle Ré Aunis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion